Abstract
We analyzed data from 92,664 clinically and molecularly confirmed Covid-19 cases in Brazil to understand the potential associations between influenza vaccination and Covid-19 outcomes. Controlling for health facility of treatment, comorbidities as well as an extensive range of sociodemographic factors, we show that patients who received a recent influenza vaccine experienced on average 8% lower odds of needing intensive care treatment (95% CIs [0.86, 0.99]), 18% lower odds of requiring invasive respiratory support (0.74, 0.88) and 17% lower odds of death (0.75, 0.89). Large scale promotion of influenza vaccines seems advisable, especially in populations at high risk of severe SARS-CoV-2 infection.
One Sentence Summary Covid-19 patients with recent influenza vaccination experience better health outcomes than non-vaccinated patients in Brazil.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data we use are derived from the Brazilian Ministry of Health. By Brazilian law (Lei 12.527/2011, art. 7, 3), all health facilities have to report Covid-19 cases within 24 hours into a public system. The Ministry of Health then ensures these data are fully de-identified, and makes them publicly available through their webpage at: https://opendatasus.saude.gov.br/dataset/bd-srag-2020
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this analysis is publicly available through the Brazilian Ministry of Health webpage at https://opendatasus.saude.gov.br/dataset/bd-srag-2020. Code to replicate the analysis is available on request from the first author.
